File:The risks of incident postacute COVID-19 composite neurologic outcomes across age compared with the contemporary control cohort.webp

English: "Composite outcomes consisted of cerebrovascular disorders (ischemic stroke, TIA, hemorrhagic stroke, and cerebral venous thrombosis), cognition and memory (memory problems and Alzheimer’s disease), disorders of the peripheral nerves (peripheral neuropathy, paresthesia, dysautonomia, and Bell’s palsy), episodic disorders (migraine, epilepsy and seizures, and headache disorders), extrapyramidal and movement disorders (abnormal involuntary movements, tremor, Parkinson-like disease, dystonia, myoclonus), mental health disorders (major depressive disorders, stress and adjustment disorders, anxiety disorders, and psychotic disorders), musculoskeletal disorders (joint pain, myalgia, and myopathy), sensory disorders (Hearing abnormalities or tinnitus, vision abnormalities, loss of smell, and loss of taste), other neurologic or related disorders (dizziness, somnolence, Guillain-Barré syndrome, encephalitis or encephalopathy and transverse myelitis), and any neurologic outcome (incident occurrence of any neurologic outcome studied). Outcomes were ascertained 30d after the COVID-19-positive test until the end of follow up. COVID-19 cohort (n = 154,068) and contemporary control cohort (n = 5,638,795). Age was transformed into restricted cubic spline function for the analyses. P value was based on 2-sided Wald Chi-Squared test on interaction between age and exposure, without multiple comparisons adjustment. A P value of <0.05 suggests that age modifies the association between COVID-19 and the neurologic outcome. The P value for cerebrovascular disorders=0.38, cognition and memory disorders=0.001, disorders of the peripheral nerves=0.15, episodic disorders<0.001, extrapyramidal and movement disorders=0.88, mental health disorders<0.001, musculoskeletal disorders<0.001, sensory disorders<0.001, other neurologic or related disorders<0.001, and any neurologic disorder=0.003."